Fei Yang
CIK 1663830 · last filed 2018-11-14
Fei Yang is a corporate insider who has filed 3 SEC Form 4 insider transactions across 1 company since 2018. 3 SEC filings were submitted jointly with Dongliang Lin.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$0
1
3
$0
Filer Profile
POLY INTERNATIONAL PLAZA, PAZHOUDADAO
GUANGZHOU, F4 510308
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| CASI Pharmaceuticals, Inc. (CASI) Delisted | 10%+ Owner | 1,019,852 | $0.28 | $285.6K | $0 | 1 | 2018-11-14 |
Recent Filings
3 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2025-09-02 | — | Notice (144) | −50,000 | -$1.86M | EDGAR |
| 2023-08-11 | — | Notice (144) | −150,000 | -$4.68M | EDGAR |
| 2018-11-14 | CASI Pharmaceuticals, Inc. (CASI) Delisted | Exer (X) | +13,598,024 | $22.98M | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.